Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808848 | 0.75 | PLAU (0.46) | LMNAMAPT | |
| SCHEMBL28825255 | 0.75 | PLAU (0.46) | LMNAMAPT | |
| SCHEMBL1132844 | 0.75 | PLAU (0.46) | LMNAMAPT | |
| SCHEMBL6919963 | 0.75 | ELANE (0.50) | ELANELMNAALDH1A1MAPTNPSR1 | |
| SCHEMBL28967076 | 0.74 | ELANE (0.49) | ELANELMNAALDH1A1CYP3A4HIF1A | |
| SCHEMBL10350646 | 0.74 | LMNA (0.60) | ELANELMNAALDH1A1MAPTNPSR1 | |
| SCHEMBL16005654 | 0.73 | FABP5 (0.49) | ELANELMNAALDH1A1MAPT | |
| SCHEMBL7758117 | 0.72 | GRM5 (0.44) | LMNAALDH1A1 | |
| SCHEMBL29607284 | 0.72 | ELANE (0.74) | ELANELMNAALDH1A1CYP3A4HIF1A | |
| SCHEMBL6925509 | 0.72 | ELANE (0.46) | ELANELMNAALDH1A1CYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642387-B2 | Dehalogenation esterification; efficient; no toxic materials | KANEKA CORPORATION (JP) | 2003-11-04 | — | — | US | disclosed |
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | KANEKA CORPORATION (JP) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | ADRB3, ADRB2, ADRB1 | ELANE 2841/4885LMNA 3951/4885ALDH1A1 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.